Abstract
Objective: Liraglutide 3.0 mg daily dose is marketed under the brand name Saxenda and was recently approved by both the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) as adjunct to a comprehensive lifestyle intervention to achieve weight loss.
Design: Human studies using liraglutide 3.0 mg daily dose were selected through search based on PubMed listings and the Clinical trials.gov database using the term “liraglutide”.
Results: During 56 weeks of treatment, liraglutide 3.0 mg treatment resulted in 5.9-8.0% weight reduction, while the placebo-subtracted weight loss was 3.9-6.0%. The proportion of treated patients with ≥ 5% weight loss was 50-76%, while the placebo-subtracted proportion was 29-46%. Liraglutide 3.0 mg treatment also induced a decrease in waist circumference, serum triglycerides, insulin resistance, blood pressure and an increase in high density lipoprotein-cholesterol (HDL-C). The most common side effects were nausea, hypoglycemia, diarrhea, constipation, vomiting and headache. In the majority of patients liraglutide 3.0 mg was well tolerated.
Conclusion: Liraglutide 3.0 mg appears to be an effective adjunct to a comprehensive lifestyle intervention to achieve weight reduction and treat obesity-related comorbidities.
Keywords: Liraglutide, glucagon-like peptide-1 agonist, weight loss, lipids, blood pressure, side effects.
Current Vascular Pharmacology
Title:The Current Role of Liraglutide in the Pharmacotherapy of Obesity
Volume: 14 Issue: 2
Author(s): Georgios A. Christou, Niki Katsiki and Dimitrios N. Kiortsis
Affiliation:
Keywords: Liraglutide, glucagon-like peptide-1 agonist, weight loss, lipids, blood pressure, side effects.
Abstract: Objective: Liraglutide 3.0 mg daily dose is marketed under the brand name Saxenda and was recently approved by both the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) as adjunct to a comprehensive lifestyle intervention to achieve weight loss.
Design: Human studies using liraglutide 3.0 mg daily dose were selected through search based on PubMed listings and the Clinical trials.gov database using the term “liraglutide”.
Results: During 56 weeks of treatment, liraglutide 3.0 mg treatment resulted in 5.9-8.0% weight reduction, while the placebo-subtracted weight loss was 3.9-6.0%. The proportion of treated patients with ≥ 5% weight loss was 50-76%, while the placebo-subtracted proportion was 29-46%. Liraglutide 3.0 mg treatment also induced a decrease in waist circumference, serum triglycerides, insulin resistance, blood pressure and an increase in high density lipoprotein-cholesterol (HDL-C). The most common side effects were nausea, hypoglycemia, diarrhea, constipation, vomiting and headache. In the majority of patients liraglutide 3.0 mg was well tolerated.
Conclusion: Liraglutide 3.0 mg appears to be an effective adjunct to a comprehensive lifestyle intervention to achieve weight reduction and treat obesity-related comorbidities.
Export Options
About this article
Cite this article as:
Christou A. Georgios, Katsiki Niki and Kiortsis N. Dimitrios, The Current Role of Liraglutide in the Pharmacotherapy of Obesity, Current Vascular Pharmacology 2016; 14 (2) . https://dx.doi.org/10.2174/1570161113666150615111951
DOI https://dx.doi.org/10.2174/1570161113666150615111951 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atherosclerotic Plaque Detection by Multi-detector Computed Tomography
Current Cardiology Reviews Vitamin D: A Pleiotropic Hormone with Possible Psychotropic Activities
Current Medicinal Chemistry The Role of Leukocyte Immunoglobulin-Like Receptors Focusing on the Therapeutic Implications of the Subfamily B2
Current Drug Targets Predicting Esophageal Varices in Cirrhotic Hepatitis C Virus Patients Using Noninvasive Measurement of Insulin Resistance Variables
Endocrine, Metabolic & Immune Disorders - Drug Targets Wii Balance Board: Reliability and Clinical Use in Assessment of Balance in Healthy Elderly Women
CNS & Neurological Disorders - Drug Targets Hyperhomocysteinemia, Pteridines and Oxidative Stress
Current Drug Metabolism Editorial [Hot topic: Importancy of a Biobank for Cardiovascular Surgery (Guest Editor: Gert J. de Borst)]
Current Cardiology Reviews Basilar Apex Aneurysms in the Setting of Carotid Artery Stenosis: Case Series and Angiographic Anatomic Study
Current Neurovascular Research Effects of an Outpatient Service Rehabilitation Programme in Patients Affected by Pulmonary Arterial Hypertension: An Observational Study
Cardiovascular & Hematological Disorders-Drug Targets Regulation of Blood Pressure by D5 Dopamine Receptors
Cardiovascular & Hematological Agents in Medicinal Chemistry Irbesartan and Hydrochlorothiazide Association in the Treatment of Hypertension
Current Vascular Pharmacology Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients
Current Pharmaceutical Design Neuronal Differentiation of Neural Progenitor Cells by Intracellular Delivery of Synthetic Oligopeptide Derived from Von Hippel-Lindau Protein
Protein & Peptide Letters Small Molecules Targeting the NMDA Receptor Complex as Drugs for Neuropathic Pain
Mini-Reviews in Medicinal Chemistry The Relationship Between Personality Types and Sexual Dysfunction
Current Women`s Health Reviews Cytokines and Hormones in the Regulation of Hypoxia Inducible Factor-1α (HIF-1α)
Cardiovascular & Hematological Agents in Medicinal Chemistry Heme Oxygenase System and Hypertension: A Comprehensive Insight
Current Pharmaceutical Design Vascular Morphology has No Direct Relationship with Atherosclerotic Plaque Burden in Patients with Symptomatic Middle Cerebral Artery Stenosis
Current Neurovascular Research PPAR-γ Agonists in Polycystic Kidney Disease with Frequent Development of Cardiovascular Disorders
Current Molecular Pharmacology Identifying Changes in the Synaptic Proteome of Cirrhotic Alcoholic Superior Frontal Gyrus
Current Neuropharmacology